Cancer Treatment Market Research Reports & Industry Analysis
Cancer is a disease characterized by uncontrolled cell proliferation. Of the more than 100 types of cancer, lung, breast, and colorectal cancer account for nearly half of new cases per year in the United States. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers.
With the growing incidence of cancer, a growing and aging world population and significant medical advances, there will continue to be phenomenal growth in the market for cancer diagnosis and treatment products.
Cancer Treatment Industry Research & Market Reports
-
Lung Cancer Diagnostics
... at a CAGR of 7.8% over the analysis period 2024-2030. Imaging Tests, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$2.3 Billion by the end of ... Read More
-
Chronic Myelogenous Leukemia Treatment
... 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Disease Specific Treatment, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$3.4 Billion by ... Read More
-
Leukemia Therapeutics
... CAGR of 5.6% over the analysis period 2024-2030. Chronic Myeloid Leukemia, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$9.1 Billion by the end of the ... Read More
-
Cervical Cancer Diagnostic Testing
... 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Pap Smear, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$5.3 Billion by the ... Read More
-
Hairy Cell Leukemia
... at a CAGR of 3.7% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$148.8 Billion by the end of the ... Read More
-
Checkpoint Inhibitor Refractory Cancer
... 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. PD-1 Inhibitor Type, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$33.0 Billion by ... Read More
-
Anaplastic Thyroid Cancer Drugs
... 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$912.1 Million by the end ... Read More
-
Neoantigen Cancer Vaccines
... at a CAGR of 20.3% over the analysis period 2024-2030. Personalized Neo-Antigen Vaccine, one of the segments analyzed in the report, is expected to record a 22.3% CAGR and reach US$52.5 Million by the end ... Read More
-
Cancer Antibody Drug Conjugates
... 2030, growing at a CAGR of 15.0% over the analysis period 2024-2030. Kadcyla, one of the segments analyzed in the report, is expected to record a 17.6% CAGR and reach US$5.7 Billion by the end ... Read More
-
Nasopharyngeal Cancer Treatment
... at a CAGR of 6.2% over the analysis period 2024-2030. Radiation Therapy, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$289.8 Million by the end of ... Read More
-
Bladder Cancer Detective Kits
... 2030, growing at a CAGR of 11.3% over the analysis period 2024-2030. Fluorescence In Situ Hybridization, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$235.7 Million ... Read More
-
Cancer Insurance
... CAGR of 9.8% over the analysis period 2024-2030. Individual Plan, one of the segments analyzed in the report, is expected to record a 11.3% CAGR and reach US$87.1 Billion by the end of the analysis ... Read More
-
Breast Cancer Screening
... at a CAGR of 5.1% over the analysis period 2024-2030. Imaging Test, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$4.8 Billion by the end of ... Read More
-
Alpha Emitters
... CAGR of 20.9% over the analysis period 2024-2030. Bone Metastasis, one of the segments analyzed in the report, is expected to record a 20.4% CAGR and reach US$993.8 Million by the end of the analysis ... Read More
-
mRNA Platform
... CAGR of -2.7% over the analysis period 2024-2030. Covid-19 Vaccine, one of the segments analyzed in the report, is expected to record a -6.3% CAGR and reach US$102.1 Billion by the end of the analysis ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Next Generation Cancer Diagnostics
... 2030, growing at a CAGR of 21.8% over the analysis period 2024-2030. qPCR & Multiplexing, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$28.2 Billion by ... Read More
-
Liver Cancer Diagnostics
... at a CAGR of 7.4% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$9.8 Billion by the end of ... Read More
-
Intraoperative Radiation Therapy
... at a CAGR of 6.0% over the analysis period 2024-2030. Systems / Accelerators, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$22.9 Million by the end ... Read More
-
Head and Neck Cancer Therapeutics
... Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. PD Inhibitors, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$2.5 Billion ... Read More
-
Tumor / Cancer Markers
... 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 10.4% CAGR The Tumor / Cancer Markers market ... Read More
-
Metastatic Bone Disease
... at a CAGR of 6.7% over the analysis period 2024-2030. Medication, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$12.3 Billion by the end of the ... Read More
-
NDDS in Cancer Therapy
... 2030, growing at a CAGR of 20.7% over the analysis period 2024-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 20.6% CAGR and reach US$67.8 Billion by the end ... Read More
-
Sunitinib Malate
... CAGR of 9.6% over the analysis period 2024-2030. Pancreatic Neuroendocrine Tumor Application, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$111.6 Million by the end of ... Read More
-
Lung Cancer Screening Software
... 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. The U.S. Market is Estimated at US$7.5 Million While China is Forecast to Grow at 6.0% CAGR The Lung Cancer Screening Software market ... Read More